business

Is Kymera Therapeutics, Inc. (KYMR) a Long-Term Biotech Winner After New Buy Rating and Coverage Launch At Canaccord?

Yahoo Finance · Jun 2, 2026, 1:55 PM · Also reported by 2 other sources

Read full story on Yahoo Finance → More top stories

Also covered by

Investing.com Benchmark reiterates Halozyme stock Buy rating on long-term potential Investing.com H.C. Wainwright initiates Upstream Bio stock coverage with buy rating

Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Is Kymera Therapeutics, Inc. (KYMR) a Long-Term Biotech Winner After New Buy Rating and Coverage Launch At Canaccord?

Also covered by

More in business